De Novo device
Avulux
Matap Ii, LLC · Light Attenuation Lenses For Migraine-Associated Light Sensitivity (QEO, Class I) · First FDA decision Aug 21, 2026, newest Aug 21, 2026Migraine and headache
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
3
Naming "Avulux"
MAUDE reports
0
Brand "Avulux", since 2015
PubMed studies
0
Mentioning "Avulux"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Avulux
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- AvuluxNew device typeDe Novo
DEN250026 · Decided Aug 21, 2026 · 424 days after receipt
Device type: Light Attenuation Lenses For Migraine-Associated Light Sensitivity (QEO) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transillumination Light Scanning or DiaphanographyNational determinationOn the books30.9Updated Apr 20, 2020
Clinical trials
Device studies on ClinicalTrials.gov that name "Avulux", any status and sponsor, newest update first.
- Migraine Headache Mitigation Utilizing AvuluxStatus unknown
Kaiser PermanenteAcademic, hospital or other
NCT06149000 · 40 participants (planned) · Start Dec 13, 2023 · Primary completion Jun 13, 2024
Device: Avulux Lenses; Placebo Lenses · For: Migraine; Headache; Photophobia
Avulux, Inc.Not on our public-company list
NCT04341298 · 78 participants · Start Apr 6, 2020 · Primary completion Aug 26, 2020
Device: Avulux®; Sham Avulux® · For: Migraine
Sites: Minneapolis, Minnesota; Columbus, Ohio · 3 sites in all
- Optical Treatment of Migraines Using the Avulux™ Optical Filter in the Form of Spectacle Lenses.Completed
Avulux, Inc.Not on our public-company list
NCT03902496 · 60 participants · Start Mar 18, 2019 · Primary completion May 17, 2019
Device: Avulux Spectacles; Sham Spectacles · For: Migraine
Sites: Columbus, Ohio
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Avulux", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QEO
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Avulux"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.